An Introduction to Cardiovascular Disease
Cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. CVDs describe a number of conditions affecting the heart and circulation, including coronary heart disease, angina, congenital heart disease, hypertension and stroke. The huge and ever-increasing burden of CVDs on individuals and healthcare systems shows the urgent ongoing need for treatments and preventive measures.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Cardiovascular Disease Content
Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity
Heart International. 2023;17(2):6-11
With the global increase in life expectancy, the proportion of elderly people in the community is expected to increase gradually. This is referred to as the ‘Coming of the Gray Dawn’ or the ‘Gray Wave’, and highlights the need for current day healthcare professionals to better understand the specific disease processes that occur in the […]
Assessment and Management of Ischaemic Heart Disease in Non-Cardiac Surgery
Heart International. 2023;17(2):19-26
Cardiac complications constitute a common cause of morbidity and mortality in the perioperative period, contributing to over a third of perioperative deaths.1 More than 230 million major surgeries are performed annually worldwide, with older patients representing an increasing proportion of the surgical population; a group with a significant burden of cardiovascular risk factors and a higher […]
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart International. 2023;17(2):12-18
Diabetes mellitus (DM) is strongly associated with severe macro- and micro-vascular complications; it is also proven to be a strong independent risk factor for developing heart failure (HF).1 In fact, the prevalence of DM is reported to be as high as 20% amongst patients with HF compared with 5–6% in the general population.2 Recent studies have […]
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
Heart International. 2023;17(2):27-34
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality both in the US and worldwide.1 There is substantial evidence from genetic, observational and interventional studies that low-density lipoprotein cholesterol (LDL-C) is causally related to the development of ASCVD in a dose-dependent fashion.2,3 Statins have been shown to substantially lower LDL-C and form the cornerstone of […]
Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.
- Summarize the various manifestations and multiple complications of SCD
- Appraise the practical considerations for the multidisciplinary management of SCD complications
- Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve Implantation Era
Heart International. 2023;17(1):13–8 DOI: https://doi.org/10.17925/HI.2023.17.1.13
The prevalence of aortic stenosis (AS) has grown over the last few decades, as life expectancy has increased. AS is the most common valvular disease in the developed world and is found in up to 9.8% of individuals aged ≥75.1–3 The wide range of ages, and the wide variability in the general health status in the […]
Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy
Heart International. 2023;17(1):2–4 DOI: https://doi.org/10.17925/HI.2023.17.1.2
Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease affecting 1 in 500 individuals worldwide.1 The disease pathogenesis of HCM is characterized by hypertrophy and myocyte disarray, along with muscle fibrosis on histopathology and intramural hyperplasia of the coronary arteries.2 HCM is diagnosed in patients with left ventricular hypertrophy having a maximum left ventricular wall thickness ≥15 mm […]
Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
Heart International. 2023;17(1):27–35 DOI: https://doi.org/10.17925/HI.2023.17.1.27
The systemic amyloidoses are a group of heterogenous diseases, which are characterized by the deposition of insoluble amyloid fibrils within the extracellular matrix of multiple organs throughout the body. Amyloid fibrils are formed from the misfolding of amyloid precursor proteins (APPs) into insoluble, beta-pleated sheets that are resistant to proteolysis. They are histologically characterized by […]
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]